At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADCT ADC Therapeutics SA
Not Yet Opened 05-03 16:00:00 EDT
4.90
+0.17
+3.59%
盘后4.90
+0.000.00%
16:55 EDT
High5.11
Low4.81
Vol323.21K
Open4.96
D1 Closing4.73
Amplitude6.24%
Mkt Cap405.79M
Tradable Cap309.82M
Total Shares82.81M
T/O1.60M
T/O Rate0.51%
Tradable Shares63.23M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
BRIEF-ADC Therapeutics Announces Updates On Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Glofitamab Or Mosunetuzumab In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.